Search Results

This year has seen the approval of several first-in-class therapies for HAE, but in a fragmented space, experts question whether they will be enough to net their developers a significant share of the entrenched market.

Be The Match BioTherapies®, an organization offering solutions for companies developing and commercializing cell and gene therapies, and Cryoport, a leading global provider of innovative products and services to the fast-growing cell & gene therapy industry enabling the future of medicine for a new era of life sciences, announced a new strategic partnership.

In anticipation of Cord Blood Awareness Month this July, Be The Match BioTherapies®, an organization offering solutions for companies developing and commercializing cell and gene therapies, announced the formation of the Be The Match BioTherapies Cord Blood Bank Alliance.

NMDP BioTherapies ℠, formerly Be The Match BioTherapies unveiled substantial upgrades to its cellular starting material offerings, including incorporating a Drug Master File (DMF) with its rapid-delivery, standard GMP leukopak to simplify regulatory filings.

Pressure from the FTC and Pfizer is building around Novo Nordisk’s bid to snatch obesity biotech Metsera. The antitrust watchdog has spotted issues with the structure of Novo’s bid, while its New York-based rival has put more money on the table.

As next-generation antibody-drug conjugates reshape cancer care, digital pathology and artificial intelligence are transforming how HER2 is measured. The advances aim to help clinicians identify low and ultra-low expressors, match patients to the right therapies and make more precise treatment decisions.

The National Marrow Donor Program® /Be The Match® and Be The Match BioTherapies® launched a new web resource page and free white paper, “Paving the way to successful cell therapy clinical trials with a comprehensive approach and patient support,” to mark Clinical Trials Day 2023.